Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

MT Newswires Live08-11

Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activity than a competing treatment and a "more convenient dosing profile," supporting the drug's potential as a best-in-class therapy, Morgan Stanley said in a report Monday.

Divesiran produced a 69% placebo-adjusted response rate across pooled treatment arms, compared with 44% for Protagonist Therapeutics' (PTGX) rusfertide, while offering dosing every six or 12 weeks versus once weekly for the competing therapy, the report said.

The investment bank also highlighted a favorable safety profile, with 91% of patients in the divesiran arms avoiding phlebotomy during the study and 44 of 48 people who completed the study choosing to enter the open label extension, according to the report.

Silence plans to present detailed Phase 2 data at the American Society of Hematology meeting in December, meet with the US Food and Drug Administration by the end of 2026 and begin a Phase 3 study in the first half of 2027, the report said.

Morgan Stanley reiterated its overweight rating on Silence Therapeutics and raised its price target to $32 from $25.

Price: 15.14, Change: -0.29, Percent Change: -1.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658911386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658911386","market":"sg","top_or_hot":-1,"title":"Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Silence <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activity than a competing treatment and a \"more convenient dosing profile,\" supporting the drug's potential as a best-in-class therapy, Morgan Stanley said in a report Monday.</p><p>Divesiran produced a 69% placebo-adjusted response rate across pooled treatment arms, compared with 44% for Protagonist Therapeutics' (PTGX) rusfertide, while offering dosing every six or 12 weeks versus once weekly for the competing therapy, the report said.</p><p>The investment bank also highlighted a favorable safety profile, with 91% of patients in the divesiran arms avoiding phlebotomy during the study and 44 of 48 people who completed the study choosing to enter the open label extension, according to the report.</p><p>Silence plans to present detailed Phase 2 data at the American Society of Hematology meeting in December, meet with the US Food and Drug Administration by the end of 2026 and begin a Phase 3 study in the first half of 2027, the report said.</p><p>Morgan Stanley reiterated its overweight rating on Silence Therapeutics and raised its price target to $32 from $25.</p><p>Price: 15.14, Change: -0.29, Percent Change: -1.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-11 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Silence <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activity than a competing treatment and a \"more convenient dosing profile,\" supporting the drug's potential as a best-in-class therapy, Morgan Stanley said in a report Monday.</p><p>Divesiran produced a 69% placebo-adjusted response rate across pooled treatment arms, compared with 44% for Protagonist Therapeutics' (PTGX) rusfertide, while offering dosing every six or 12 weeks versus once weekly for the competing therapy, the report said.</p><p>The investment bank also highlighted a favorable safety profile, with 91% of patients in the divesiran arms avoiding phlebotomy during the study and 44 of 48 people who completed the study choosing to enter the open label extension, according to the report.</p><p>Silence plans to present detailed Phase 2 data at the American Society of Hematology meeting in December, meet with the US Food and Drug Administration by the end of 2026 and begin a Phase 3 study in the first half of 2027, the report said.</p><p>Morgan Stanley reiterated its overweight rating on Silence Therapeutics and raised its price target to $32 from $25.</p><p>Price: 15.14, Change: -0.29, Percent Change: -1.88</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTGX","symbol_name":"Protagonist Therapeutics Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658911386","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658911386","pubTimestamp":1786460739,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Silence Therapeutics'  Phase 2 results for divesiran in polycythemia vera showed stronger activity than a competing treatment and a \"more convenient dosing profile,\" supporting the drug's potential as a best-in-class therapy, Morgan Stanley said in a report Monday.Divesiran produced a 69% placebo-adjusted response rate across pooled treatment arms, compared with 44% for Protagonist Therapeutics'  rusfertide, while offering dosing every six or 12 weeks versus once weekly for the competing therapy, the report said.The investment bank also highlighted a favorable safety profile, with 91% of patients in the divesiran arms avoiding phlebotomy during the study and 44 of 48 people who completed the study choosing to enter the open label extension, according to the report.Silence plans to present detailed Phase 2 data at the American Society of Hematology meeting in December, meet with the US Food and Drug Administration by the end of 2026 and begin a Phase 3 study in the first half of 2027, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTGX":"Protagonist Therapeutics Inc","BK4139":"生物科技","SLN":"Silence Therapeutics Plc","LENZ":"Therapeutics","BK4007":"制药","BK4539":"次新股"},"translate_title":"摩根士丹利表示，Silence Therapeutics 的分散数据支持一流的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLN":1,"LENZ":1.5,"PTGX":1},"content_text":"Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activity than a competing treatment and a \"more convenient dosing profile,\" supporting the drug's potential as a best-in-class therapy, Morgan Stanley said in a report Monday.Divesiran produced a 69% placebo-adjusted response rate across pooled treatment arms, compared with 44% for Protagonist Therapeutics' (PTGX) rusfertide, while offering dosing every six or 12 weeks versus once weekly for the competing therapy, the report said.The investment bank also highlighted a favorable safety profile, with 91% of patients in the divesiran arms avoiding phlebotomy during the study and 44 of 48 people who completed the study choosing to enter the open label extension, according to the report.Silence plans to present detailed Phase 2 data at the American Society of Hematology meeting in December, meet with the US Food and Drug Administration by the end of 2026 and begin a Phase 3 study in the first half of 2027, the report said.Morgan Stanley reiterated its overweight rating on Silence Therapeutics and raised its price target to $32 from $25.Price: 15.14, Change: -0.29, Percent Change: -1.88","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658911386","isCrawlerRequest":true}